Department of Pediatrics, Division of Endocrinology, School of Medicine, Stanford University, Room H314, Stanford, CA, 94305, USA.
Curr Osteoporos Rep. 2017 Aug;15(4):271-282. doi: 10.1007/s11914-017-0371-2.
Osteoporosis is an under-recognized complication of chronic illness in childhood. This review will summarize recent literature addressing the risk factors, evaluation, and treatment for early bone fragility.
Criteria for the diagnosis of pediatric osteoporosis include the presence of low trauma vertebral fractures alone or the combination of low bone mineral density and several long bone fractures. Monitoring for bone health may include screening for vertebral fractures that are common but often asymptomatic. Pharmacologic agents should be offered to those with fragility fractures especially when spontaneous recovery is unlikely. Controversies persist about the optimal bisphosphonate agent, dose, and duration. Newer osteoporosis drugs have not yet been adequately tested in pediatrics, though clinical trials are underway. The prevalence of osteoporosis is increased in children with chronic illness. To reduce the frequency of fragility fractures requires increased attention to risk factors, early intervention, and additional research to optimize therapy and potentially prevent their occurrence.
骨质疏松症是儿童慢性疾病中一种未被充分认识的并发症。本综述将总结近期有关早期骨骼脆弱性的危险因素、评估和治疗的文献。
儿科骨质疏松症的诊断标准包括单纯存在低创伤性椎体骨折,或低骨密度和多处长骨骨折同时存在。监测骨骼健康可能包括筛查常见但通常无症状的椎体骨折。对于有脆性骨折的患者,尤其是自发性恢复不太可能的患者,应提供药物治疗。关于最佳双膦酸盐药物、剂量和疗程仍存在争议。新型骨质疏松症药物尚未在儿科中进行充分测试,尽管正在进行临床试验。患有慢性疾病的儿童骨质疏松症的患病率增加。要减少脆性骨折的发生频率,需要更加关注危险因素,早期干预,并进行更多的研究,以优化治疗并可能预防其发生。